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1. Introduction 
For over fifty years, people have used antibiotics to treat illnesses caused by pathogens. 
However, the excessive and inappropriate use of these antibiotics in clinical treatment of 
humans and animals has increased pathogen resistance to these compounds, turning them 
into less effective agents. There has also been an increase in the generation of multidrug-
resistant pathogens, primarily bacteria and fungi that resist the effects of most currently 
available antibiotics (Heuer et al., 2006; Field, 2010). 
Until now, the pharmaceutical industry is facing this problem by looking for new antibiotics 
or modifying existing ones. However, pathogens have proven to have the ability to quickly 
develop and disseminate resistance mechanisms, which compromises this strategy, 
becoming it less effective. This clearly shows the need to develop new biomedical 
treatments with different action mechanisms from those of conventional antibiotics (Parisien 
et al., 2008). 
This problem has led that efforts being made on research and development of new 
biomedical alternatives, among which antimicrobial peptides (AMPs) are considered one of 
the most promising options. AMPs are produced by a wide variety of organisms as part of 
their first line of defense (eukaryotes) or as a competition strategy for nutrients and space 
(prokaryotes). These molecules are usually short peptides (12-100 amino acid residues); 
have a positive charge (+2 to +9), although there are also neutral and negatively charged. 
They are amphipathic and have been isolated from bacteria, plants and animals, including 
humans; which give us an overview of the enormous structural diversity of these molecules 
and their different action mechanisms (Murray & Liu, 2008). 
The continuous discovery of new AMPs groups in diverse organisms has turned these natural 
antibiotics into the basic elements of a new generation of potential biomedical treatments 
against infectious diseases in humans and animals. Besides the above, the broad spectrum of 
biological activities reported for these molecules suggests a potential benefit in cancer 
treatment, viral and parasitic infections and in the modulation of the immune system, which 
reinforces the importance of studying these molecules (Mercado et al., 2005; Schweizer, 2009). 
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The contents of this chapter shows the importance of AMPs for living organisms, not only 
from the antimicrobial point of view, but also in bacterial cell communication processes, 
immune response modulation in animals and plant defense mechanisms. It also emphasizes 
on AMPs’ biological and structural diversity, as well as their various action mechanisms 
and, finally, their possible biotechnological development for the pharmaceutical industry is 
discussed.  
2. AMPs from Gram positive bacteria and their classification 
During their evolution, bacteria have acquired mechanisms that allow them to have success 
in competition for nutrients and space in their habitat. These mechanisms include from the 
enhancement of chemotaxis systems to the acquisition of defense systems such as the 
production of antimicrobial peptides (AMPs), also called bacteriocins (Riley & Wertz, 2002). 
AMPs are biologically active molecules that have the ability to inhibit the growth of other 
members of the same specie or members of different bacterial genres (Cotter et al., 2005b). 
These molecules are synthesized by the vast majority of bacterial groups; in fact, it has been 
proposed that 99% of bacteria produce at least one, as they have been found in most 
examined species, covering Gram positive and Gram negative bacteria and archaea; in 
addition they are used as an important tool in evolutionary and ecological studies 
(Klaenhammer, 1988). Also, the successful commercial development of nisin (produced by 
Lactococcus lactis) and the use of molecular biology and genetic engineering tools in recent 
years have provoked a resurgence in AMPs studies, particularly in relation to their potential 
biomedical applications (Cotter et al., 2005a, b; Bierbaum & Sahl, 2009; Field et al., 2010). 
AMPs from Gram positive bacteria represent a heterogeneous group of chemical molecules; 
nevertheless only three main categories have been established based on their structural 
modifications, size, thermostability and action mechanisms (Table 1). Class I (lantibiotics) is 
constituted by cationic peptides ranging from 19 to 38 amino acid residues, which undergo 
posttranslational modifications and exert their effect at membrane and cell wall levels. Their 
posttranslational modifications are diverse; the most important involve dehydration 
reactions of serine and threonine residues, resulting in the formation of didehydroalanine 
(Dha) and didehydroaminobutyric acid (Dhb), respectively (Cotter et al., 2005b). The 
reaction of these amino acids with the thiol group (SH) of a cysteine residue generates a 
thioether bond producing lanthionine (in the case of Dha) and β-methyl-lanthionine (in the 
case  of Dhb). The formation of these bonds within the peptide generates a series of 
"globular" structures that are characteristic of lantibiotics. This AMPs class is further divided 
into subgroups A and B, having nisin as the representative member of subgroup A, while 
mersacidin, produced by bacteria of the Bacillus genus, is a member of subgroup B (Table 1) 
(McAuliffe et al., 2001; Cotter et al., 2005a). 
On the other hand, class II (non lantibiotics) is formed by AMPs constituted by 30 to 60 
amino acid residues; they do not contain lanthionine, are thermostable and induce the 
formation of pores in the membrane of target cells. These peptides in turn are divided into 
subclasses IIa, IIb, IIc and IId (Table 1). Subclass IIa is the largest and its members posses the 
amino terminal motif YGNGVXCXXXXVXV (X indicates any amino acid residue) and have 
one or two disulfide bonds. AMPs from this subclass show specific activity against the 
bacteria Listeria monocytogenes (Ennahar et al., 2000). Leucocin A from Leuconostoc gelidum is 
a representative member of this subclass (Hastings et al., 1991). 
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Class 
Subclass 
Representative 
AMPs 
Producing bacteria 
I Lantibiotic I A Nisin 
Lactococcus lactis 
 
I Lantibiotic I B Mersacidin 
Bacillus spp. 
 
II Non lantibiotic IIa Leucocin A 
Leuconostoc gelidum 
 
II Non lantibiotic IIb Lactococcin G 
L. lactis 
 
II Non lantibiotic IIc AS-48 enterocin 
Enterococcus faecalis 
 
II Non lantibiotic 
 
III Proteins 
IId 
 
 
 
Lactococcin A 
 
Helveticin J 
L. lactis 
 
L. helveticus 
Table 1. Classification of AMPs found in Gram positive bacteria (Cotter et al., 2005a; Drider 
et al., 2006) 
Subclass IIb comprises AMPs that require the combined action of two peptides in order to 
have activity; these peptides do not show inhibitory activity on an individual basis. 
Lactococcin G from L. lactis is a representative member of this subclass (Moll et al., 1996). 
The AMPs that make up subclass IIc posses a cyclic structure as a result of the covalent 
binding of their carboxyl and amino terminal ends; AS-48 enterocin from Enterococcus 
faecalis is one of the main representatives of this subclass (Sánchez et al., 2003). Subclass IId 
is formed by a variable group of linear peptides, among which lactococcin A from L. lactis is 
found (Holo et al., 1993). Finally, the class III is formed by proteins with molecular masses 
higher than 30 kDa, the helveticin J from L. helveticus, is an example (Drider et al., 2006). 
2.1 Genes involved in AMPs synthesis and expression regulation from Gram positive 
bacteria 
The genes encoding AMPs are organized as operons, which could contain several genes 
involved in the synthesis and regulation. For example, the enterocin A operon of 
Enterococcus faecium contains the entA gene that codifies for pre-enterocin; in addition, this 
operon contains the genes that codify for the protein involved in the self-protection of the 
producing strain (entI), the AMP synthesis induction gene (entF), genes for proteins 
involved in extracellular transport (entT, D), as well as the genes of proteins related to the 
AMP synthesis regulation (entK, R) (Nilsen et al., 1998). In the case of lantibiotics, these have 
additional genes that codify for AMP modification enzymes (McAuliffe et al., 2001). 
AMPs synthesis regulation is mediated by two signal transduction systems constituted by 
two or three components. Diverse factors activate these systems, which include: the 
presence of other competing bacteria (Maldonado et al., 2004), temperature or pH stress 
(Ennahar et al., 2000) and a mechanism of "quorum sensing" (Kuipers et al., 1998). An 
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interesting example is the three-component system that regulates the synthesis of enterocin 
A in E. faecium, which is regulated by the mechanism of quorum sensing. This system 
includes: 1) a histidine kinase (HK), located in the cytoplasmic membrane which detects 
extracellular signals, and 2) a cytoplasmic response regulator (RR) that mediates an adaptive 
response, which usually is a change in the gene expression and an induction factor (IF), 
whose presence is detected by the HK protein (Figure 1, stage 1) (Cotter et al., 2005b). In this 
case, the system is triggered as a result of an IF excess concentration through a slow 
accumulation during cell growth, the HK detects this concentration and initiates the 
signaling cascade that activates the transcription of genes involved in enterocin A synthesis 
(Figure 1, stages 2 and 3) (Ennahar et al., 2000). Other examples of this type of regulation 
include several class II members such as sakacin P and A from Lactobacillus sake (Hühne et 
al., 1996). Moreover, some examples of regulation mediated by two-component systems 
include numerous lantibiotics, for example, subtilin from Bacillus subtilis and nisin from L. 
lactis. In these systems AMPs have a dual function, as they have antimicrobial activity and 
also act as a signal molecule by inducing its own synthesis (not shown) (Kleerebezem, 2004). 
2.2 AMPs secretion and self-protection mechanisms from Gram positive bacteria 
AMPs are synthesized as inactive pre-peptides containing a signal peptide at the N-terminal 
region (Figure 1, stage 3). This signal keeps the molecule in an inactive form within the 
producing cell facilitating its interaction with the carrier, and in the case of lantibiotics plays 
an important role in the pre-peptide recognition by the enzymes that perform 
posttranslational modifications. The signal peptide may be proteolytically removed during 
transport of the pre-peptide into the periplasmic space by the same transport proteins (ATP-
dependent ABC membrane transporters, which may also contain a proteolytic domain) 
(Figure 1, stage 4), or by serine-proteases present on the outside of the cell membrane. Thus, 
the carboxyl terminus is separated from the signal peptide and is released into the 
extracellular space to produce the biologically active peptide (Figure 1, stage 5) (Ennahar et 
al., 2000; Cotter et al., 2005b). 
AMPs producing bacteria possess proteins that protect them from the action of their own 
peptides. The exact molecular mechanisms by which these proteins confer protection to the 
producing bacteria are unknown; however, two protection systems have been proposed, 
which, in some cases act in the same bacteria (Kleerebezem, 2004). The protection can be 
provided by a specific protein that sequesters and inactivates the AMP, or that binds to the 
AMP receptor causing a conformational change in its structure making it inaccessible to the 
AMP (Figure 1, stage 6) (Venema et al., 1994). The second system is constituted by the ABC 
transport proteins, which in some cases provide the protection mechanism through the 
expulsion of the membrane-binding AMPs (Otto et al., 1998). 
2.3 AMPs spectrum and action mechanisms from Gram positive bacteria 
In general, the antibacterial action spectrum of AMPs of Gram positive bacteria is restricted 
to this bacterial group. However, there are several molecules with a wide range of action, 
inhibiting the growth of Gram positive (McAuliffe et al., 2001) and Gram negative bacteria 
(Motta et al., 2000), human pathogenic fungi (De Lucca & Walsh, 1999) and viruses (Jenssen 
et al., 2006). Also, AMPs have activity against various eukaryotic cells, such as human and 
bovine erythrocytes (Datta et al., 2005). With regard to their antimicrobial activity, AMPs 
possess essential characteristics in order to carry out the activity, regardless of their target  
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Fig. 1. Regulation of the synthesis of enterocin A from Enterococcus faecium (non-lantibiotic). 
Stage 1, the EntK protein detects the presence of the induction factor (IF) and 
autophosphorylates. Stages 2 and 3, the phosphate group is transferred to the EntR response 
regulator, which activates genes involved in the synthesis of the pre-peptide (pre-enterocin 
A) and of the IF. Stages 4 and 5, the pre-enterocin A and the IF are transported to the outside 
by the EntT and EntD proteins, and processed by the same system, releasing the active 
enterocin A and the IF. Stage 6, the EntI protein protects the producing bacteria from the 
effect of enterocin A (Ennahar et al., 2000; Cotter et al., 2005b) 
cell. These include, 1) a net positive charge which favors its interaction with the negatively 
charged lipopolysaccharide membrane of Gram negative bacteria, or with teichoic and 
lipoteichoic acids from the wall of Gram positive bacteria; 2) hydrophobicity, required for 
the insertion of the AMP in the cell membrane; and 3) flexibility, which allows a 
conformational change from a soluble state to one of membrane interaction. These 
characteristics vary from molecule to molecule; however, all are important for antimicrobial 
activity (Jenssen et al., 2006). 
It has been shown that the action targets of AMPs studied to date are the cell membrane and 
wall, as well as some important enzymes for cell metabolism. The action mechanisms 
include: i) pore formation in the cell membrane, causing loss of cell contents, this is the 
mechanism described for nisin (Enserink, 1999) and lactococcin A from L. lactis (Van Belkum 
et al., 1991); ii) cell wall synthesis inhibition, this mechanism has been described for 
mersacidin, which involves binding to lipid II, the main transporter of peptidoglycan 
subunits (UDP-Mur -Nac-pentapeptide-GlcNAc) (Brotz et al., 1995); and iii) inhibition of the 
activity of enzymes such as phospholipase A2, which is involved in membrane repair; this is 
the reported mechanism for cinamicin from Streptomyces cinnamoneus (Marki et al., 1991). 
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Additionally, there have been reports of AMPs that possess a dual action mechanism, such 
as nisin (Figure 2) (Breukink et al., 1999; Bierbaum & Sahl, 2009). The most accepted model 
showing the dual action mechanism of nisin proposes that it initially binds to the cell wall 
by electrostatic attraction, events that are facilitated due to the positive charge of this 
peptide and negative charges of cell wall components (Figure 2, stage 1). Subsequently, nisin 
binds to lipid II, the main transporter of peptidoglycan subunits, and uses this molecule to 
anchor itself to the cell membrane (Figure 2, stage 2). Then, it changes its orientation with 
respect to the membrane and inserts itself in it; this involves the translocation of its carboxyl 
terminus through the membrane. Finally, the binding of different peptides in the insertion 
site leads to the formation of a transmembrane pore that allows the exit of important 
molecules such as amino acids and ATP, leading the bacteria to a rapid cell death (Figure 2, 
stage 3) ( Wiedemann et al., 2001; Bierbaum & Sahl, 2009). 
2.4 AMPs resistance from Gram positive bacteria 
Resistance development in pathogenic bacteria that are normally sensitive to AMPs is of 
great interest because of their possible use in biomedical therapies, as bacterial resistance 
might limit their use. Within a particular bacterial species there may be naturally resistant 
members to AMPs or resistance may arise as a result of continuous exposure; which are 
known as intrinsic and acquired resistance, respectively (Xue et al., 2005). 
Most research in this area has focused on specific AMPs such as nisin and class IIa members. 
In the first case, L. monocytogenes, L. innocua, Streptococcus pneumoniae and S. bovis resistant 
mutants have been detected, whose resistance has been correlated to changes in the wall and 
cell membrane (Gravesen et al., 2002). More specifically the synthesis and incorporation of 
various structural components to the membrane (Li et al., 2002) and the cell wall (Mantovani 
& Russell, 2001) have been observed in the mutants, which has favored an increase in 
positive charges in these cell structures and reduced the antibacterial activity of nisin (which 
has a net positive charge). Likewise, changes in the fluidity of cell membrane (Verheul et al., 
1997) and an increase in the thickness of the cell wall of some mutant bacteria have been 
observed (Maisnier & Richard, 1996; Murray & Liu, 2008). 
The mechanisms of resistance to type II AMPs have been studied in strains of L. 
monocytogenes, essentially towards class IIa peptides, in which the resistance is related to 
several factors including reduced expression of a permease that acts as a potential receptor 
(Dalet et al., 2001), as well as changes in membrane fluidity (Vadyvaloo et al., 2002), and in 
cell surface charges (Vadyvaloo et al., 2004). The importance of studying the resistance lies 
not only in the possible long term ineffectiveness of AMPs, but also in generating 
knowledge that could serve as a basis for strategies to improve the therapeutic potential of 
these antimicrobial molecules, i.e. the development of protein engineering strategies to 
improve the biological properties of AMPs (Field et al., 2010). 
Currently, the existence of natural AMPs variants suggests that there is flexibility in the 
location of some important amino acid residues for antimicrobial activity, which indicates 
that it is possible to generate mutants with changes that increase this activity. Thus, 
additional studies are needed to determine the mechanisms of resistance to AMPs, as well as 
the frequency with which it occurs (Cotter et al., 2005a). 
2.5 Current and potential Gram positive AMPs applications in biomedical therapies 
AMPs null toxicity to humans and animals and activity directed towards pathogenic 
bacteria has allowed investigating their potential applications in biomedical therapies. In 
particular, the action mechanisms of these peptides and their activity against pathogens 
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Fig. 2. Model showing the dual action mechanism of nisin from Lactococcus lactis. Stage 1, 
nisin has a net positive charge that increases its interaction with the negative charges of the 
cell wall components. Stage 2, nisin binds to lipid II, the main transporter of peptidoglycan 
subunits from the cytoplasm to the cell wall, interfering with its synthesis, leading the 
bacteria to cell death. Stage 3, in addition, several nisin molecules use lipid II to anchor and 
insert themselves into the cell membrane and begin the formation of pores, leading the 
bacteria to a rapid cell death (Wiedemann et al., 2001; Cotter et al., 2005a) 
resistant to conventional antibiotic therapy, making them an attractive option as 
antimicrobial agents (Table 2) (Cotter et al., 2005a, b; Piper et al., 2009). Broad spectrum 
AMPs or bioengineered AMPs could be used against Gram positive pathogens of humans 
and animals. For example, lacticin 3147 from L. lactis has shown in vitro activity against 
methicillin-resistant Staphylococcus aureus (MRSA); vancomycin-resistant enterococci (VRE); 
vancomycin-intermediate S. aureus (VISA); streptococci, S. pneumoniae, S. pyogenes, S. 
agalactiae, S. dysgalactiae, S. uberis, S. mutans; Clostridium botulinum and Propionibacterium 
acnes (Galvin et al., 1999; Piper et al., 2009). In the same way, it has been created two nisin 
variants by bioengineered (nisin V and nisin T) with enhanced antimicrobial activity against 
Gram positive pathogens like MRSA, VRE, VISA, Clostridium difficile, L. monocytogenes and B. 
cereus (Field et al., 2010). 
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AMPs and 
producing 
strain 
Activity Potential biomedical applications 
Nisin 
L. lactis 
Inhibits Gram positive 
and Gram negative 
bacteria, including 
Helicobacter pylori 
Bacterial mastitis, oral hygiene, treatment 
of methicillin-resistant Staphylococcus, 
enterococcal infections, topical 
formulations, deodorants and cosmetics, 
treatment of peptic ulcers and 
enterocolitis 
 
Epidermin 
S. epidermidis 
 
Inhibits 
Propionibacterium acnes, 
staphylococci, 
streptococci 
Acne, folliculitis, impetigo 
 
Mersacidin 
Bacillus spp. 
 
 
Cinamicin 
Streptomyces 
cinnamoneus 
 
Inhibits staphylococci 
and streptococci strains 
 
 
Phospholipase A2 
inhibitor, angiotensin 
and HSV converting 
enzyme 
 
Treatment of methicillin-resistant 
Staphylococcus aureus and streptococcal 
infections 
 
Inflammation reduction, blood pressure 
regulation and viral infection treatment 
Table 2. A few Gram positive AMPs examples and their potential biomedical use (Cotter et 
al., 2005a) 
On the other hand, in vivo experiments using animal models have shown positive results 
after using lantibiotics, such as mersacidin and nisin in the treatment of respiratory tract 
infections caused by S. aureus MRSA (Kruszewska et al., 2004; De Kwaadsteniet et al., 2009), 
and Streptococcus pneumonia (Goldstein et al., 1998), in addition to skin care and oral 
therapies, such as tooth paste for prevention of teeth loss, bad breath and gingivitis (Howell 
et al., 1993; Arauz et al., 2009). Likewise, nisin has showed that has the potential for 
treatment of human mastitis (Fernández et al., 2008). 
The Oragenics pharmaceutical company has realized extensive preclinical testing on the 
lantibiotic mutacin MU1140 of S. mutans, which has demonstrated activity against wide 
variety of disease-causing Gram positive bacteria, including MRSA, VRE, Mycobacterium 
tuberculosis, and anthrax. For the complete trials, this company has created the synthetic 
version MU1140-S, and they expect to conclude the preclinical testing in 2011. Likewise, in 
New Zealand, the BLIS K12® dietary supplement is sold as an inhibitor of bacteria 
responsible for bad breath, because it contains a strain of S. salivarus that produces 
salivaricin A2 and B peptides (Tagg, 2004). 
In relation to animal disease, several AMPs have been proposed as potential alternatives to 
bovine mastitis control. Nisin has activity against mastitis pathogens and has been 
formulated in Wipe Out® and Mast Out®, commercially available products (Ryan et al., 
1998; Wu et al., 2007). Also, AMPs produced by S. aureus, S. epidermidis and Streptococcus 
gallolyticus have been tested against strains of both S. aureus and Streptococcus species 
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isolated from bovine mastitis (Varella et al., 2007; Pieterse et al., 2008). Finally, B. 
thuringiensis AMPs have showed inhibitory action against S. aureus isolates from bovine 
mastitis (Barboza-Corona et al., 2009).  
From a non antimicrobial medical perspective, AMPs such as cinamicin may have different 
biomedical applications, because this peptide inhibits the function of phospholipase A2 and 
the angiotensin converting enzyme, which are involved in the immune system and in 
maintaining blood pressure in humans, respectively; so that they could be used in 
inflammatory processes and in blood pressure regulation (Ennahar et al., 2000) (Table 2). In 
the same way, nisin has shown contraceptive activity (Gupta et al., 2009) and protector 
activity in rabbits and mice vaginas in in vitro and in vivo studies (Reddy et al., 2004). 
3. AMPs from Gram negative bacteria and their classification 
The term "bacteriocinogenicity" is used to describe the ability of Gram negative bacteria to 
synthesize and excrete AMPs (Daeschel et al., 1990). These molecules were first detected in 
Escherichia coli and were called colicins. Later, they were found in Gram positive bacteria 
and have been studied with great interest, especially those produced by lactic acid bacteria, 
which can be used in food preservation because its activity against Gram negative bacteria, 
the leading cause of food poisoning (Hardy, 1975; Tagg et al., 1976). Colicin V from E. coli 
and pyocin from Pseudomonas aeruginosa, are the two best studied peptides in the Gram 
negative bacteria group (Table 3) (Jack et al., 1995). 
The colicin group has been taken as the representative group of Gram negative AMPs, 
although there are differences between them. Pyocins are AMPs of high molecular weight 
synthesized by P. aeruginosa strains, which could participate in establishing and protection 
of bacteria. There are three types of pyocins: R, F and S, which resemble the tails of 
bacteriophages of the Myoviridae family. Type R pyocins show broad similarities with the 
fibers of the tails of these phages. Type R pyocins are contractile and not flexible, the F type 
are flexible, but are not contractile; and the S type are susceptible to proteases (Michel-
Briand & Baysse, 2002; Waite & Curtis, 2009). 
The colicins are proteins between 29 and 90 kDa, which have binding, transport and specific 
activity domains, same as those found in pyocins. The secretion of colicins is carried out in  
cell lysis, which involves their death (Riley & Wertz, 2002; Sano et al., 1993). Other kind of 
AMPs produced by E. coli and other enterobacteria are the microcins, which are a group of 
circular peptides, from which microcin J25, produced by E. coli AY25, has been taken as a 
model (Craik et al., 2003). Microcins are low molecular weight molecules under 10 kDa, 
which play an important role in competition for colonization of the gastrointestinal tract. 
They are generally hydrophobic, highly stable in relation to heat, extreme pH and proteases 
(Duquesne et al., 2007). Some other Gram negative AMPs are: Serracin P, produced by 
Serratia plymithicum J7; mundticin KS, synthesized by Enterococcus mundtii, NFRI 7393 and 
caratovoricin, produced by Pectobacterium carotovorum subsp. carotovorum (Jabrane et al., 
2002; Kawamoto et al., 2002; Yamada et al., 2008). 
3.1 Genes involved in Gram negative AMPs synthesis 
The genes required for colicin synthesis are encoded usually in plasmids, and consist of a 
colicin gene, a gene for immunity and a lysis gene. Most of the genes coding for AMPs in 
Gram negative bacteria probably derived from recombination of existing AMPs genes. 
Colicins contains a central domain (50%) involved in the recognition of the target cell 
receptor; a N-terminal domain (> 25%) responsible for the translocation of the peptide to the 
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AMPs and 
producing bacteria 
Group Main features 
Colicin 
Escherichia coli 
Group A N-terminal domain rich in glycine (~20-40%) 
 Group B N-terminal domain rich in glycine (~10-20%) 
Microcins 
E. coli 
Class I 
The self-immunity genes are not close to microcin 
structural gene 
 Class IIa Cluster of four genes encoded in plasmids 
 Class IIb 
Chromosomally encoded, have a complex 
transcriptional organization 
Pyocins 
P. aeruginosa 
Type R 
Resemble the fibers of the tails of bacteriophages of 
the Myoviridae family and are contractile but are not 
flexible 
 Type F Flexible, but are not contractile peptides 
 Type S Susceptible to proteases 
Table 3. Principal groups of Gram negative AMPs 
target cell, and the rest of the protein has the lethal and immunity activities. Pyocin genes 
from P. aeruginosa PAO1 strain are found in the chromosome, are present as a group of 16 
open reading frames, of which 12 are analogous to bacteriophage genes (Riley & Wertz, 
2003; Williams et al., 2008). Microcins are encoded in plasmids or the chromosome; a typical 
gene clusters include the microcin precursor, the self-immunity factor, the secretion proteins 
and frequently the post-translational modification enzymes (Duquesne et al., 2007). 
3.2 Synthesis and AMPs secretion from Gram negative bacteria 
The production of colicins is performed under stress, reason why it is mediated by the SOS 
regulon (Gillor et al., 2008). The number of cells producing colicin in culture is very small, 
but the proportion increases when cells are exposed to stressors such as mitomycin and UV 
light (Jack et al., 1995). Pyocin synthesis in P. aeruginosa PAO1 occurs in a similar way. 
Synthesis starts when the stressor (which could cause damage to DNA) stimulates the 
expression of the RecA protein, whose main function is the repair of damaged DNA and to 
degrade the repressor protein (PRTR) to initiate the expression of the prtN activator gene; 
the PrtN protein then activates the expression of genes that codify for pyocins (Waite & 
Curtis, 2009). Microcins are also synthesized under stress conditions like a pro-microcin that 
is secreted to the medium after suffering a cut of 15 to 37 amino acid residues to release the 
active microcin; only the MccC7/C5 AMP from E. coli does not undergo this change 
(Duquesne et al., 2007; Novikova et al., 2007). 
3.3 Gram negative AMPs action mechanisms 
Colicins generally present three action mechanisms: some of them form pores or ion 
channels in the membrane, others have nuclease activity (colicin E2 and pyocin S3), others 
inhibit the synthesis of macromolecules (colicin E3), or as in the case of microcin, the action 
mode depends upon the organism that it is acting on. Microcin J25 acts on E. coli inhibiting 
RNA polymerase, while on Salmonella enterica forms pores in the membrane (Pugsley, 1984; 
Craik et al., 2003). 
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AMPs whose action is to form pores in the membrane destroy the organism by altering the 
membrane permeability, affecting the normal flow of ions like potassium, magnesium, 
sodium and chloride, as well as inhibiting ATP synthesis through the dissipation of the 
membrane electric potential and of the pH gradient. Examples of these AMPs are: glycinecin 
A from Xanthomonas campestris; A, E1, K, Ia and Ib colicins from E. coli; pyocin S5 from P. 
aeruginosa and xenocin from Xenorhabdus nematophila (Pham et al., 2004; Cascales et al., 2007; 
Singh & Banerjee, 2008; Zhang et al., 2010). Once released, some AMPs are attached to a 
membrane receptor present in the target cell, afterwards enter to the cell, usually helped by 
Tol-like  proteins, and finally they may have access to intracellular targets (Lazaroni et al., 
2002; Singh & Banerjee, 2008). 
The AMPs that have nuclease activity enter to the cell and bind to tRNA or rRNA and break 
it at specific sites, thus inhibiting protein synthesis. Also, several AMPs can degrade nucleic 
acids without any specificity, for example: colicins E5, D and E7, and pyocins S1, S2, S3, S4 
and AP41 (Masaki & Ogawa, 2002; Michel-Briand & Baysse, 2002; Hsia et al., 2005). 
In the case of microcins, the facts that have a great diversity of post-translational 
modifications suggests that also have a great variety of action mechanisms; however, they 
show the typical nuclease and pore-formation mechanisms, although the latter is related to 
the production of siderophores. This dual mechanism of siderophore production and pore 
formation has been found in some microcins such as MccE492, produced by Klebsiella 
pneumoniae RYC492. The mechanism works as follows: the bacteria produces the 
siderophore to chelate environmental Fe3+, thus preventing its use by other microorganisms; 
afterwards the siderophore undergoes post-translational modification and creates a 
glycopeptide capable of forming pores in the membrane of competing bacteria (Thomas et 
al., 2004; Duquesne et al., 2007; Nolan et al., 2007; Mercado et al., 2008).  
3.4 AMPs resistance from Gram negative bacteria 
Resistant mechanisms for Gram negative AMPs, different to self-immunity, have been 
described. It has been found some strains of E. coli resistant to others E. coli colicins, which 
have a Tol or Ton mechanisms altered, but is very specific and only works with the specific 
colicin. These resistant strains have been used to study the Tol and Ton mechanism (Braun 
et al., 1994). The pyocin resistant strains of Neisseria gonorrhoeae and Haemophilus ducreyi, 
have been found to be associated with structural differences in the outer membrane 
lipooligosaccharides in both species (John et al., 1991; Filiatrault et al., 2001). An E. coli K12 
microcin resistant has been found, this strain possess a YojI protein which works as microcin 
J25 efflux pump (Socias et al., 2009). These examples show the variety of mechanisms 
displayed by bacteria to counteract the AMPs activity. 
3.5 Potential Gram negative AMPs applications in biotechnology and biomedical 
therapies 
The consumption of AMPs producing bacteria or the consumption of the purified peptides 
can be useful in establishing probiotic microorganisms in the gastrointestinal tract of 
humans and animals, which can lead to health improvements (Gillor et al., 2009). It has been 
found that in cystic fibrosis patients with an P. aeruginosa infection this organism produces 
pyocins that inhibit the growth of its closest competitors, so it could also be used as a 
therapeutic agent in these kind of patients and minimize the effects of the infection, that 
besides rooting out other susceptible. P. aeruginosa strains, also has an effect on Haemophilus, 
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Neisseria and Campylobacter. Regarding the latter, peritonitis treatment in mice has been 
successful (Scholl & Martin, 2008; Waite & Curtis, 2009; Williams et al., 2008). In other 
studies, colicin E1 has shown to inhibit the growth of E. coli O157:H7 in vitro, and the next 
step is to try it in meat and in the feeding of cattle to avoid the growth of E. coli O157:H7 in 
the gut (Callaway et al., 2004). The pyocin R-Type is studied as an antibiotic against E. coli, 
Salmonella, Yersinia pestis and Pseudomonas species by AvidBiotics Corp., with the name 
“Avidocin™ Proteins”, but there is not still commercially available. 
4. Animal and plant AMPs 
As part of the defense mechanisms of multicellular organisms it can be found the 
production of compounds to eliminate invading microorganisms. Among these AMPs stand 
out; they are components of the innate immune response in higher eukaryotes. AMPs are 
mostly small, amphipathic and cationic peptides that possess diverse functions in addition 
to their antimicrobial properties. Currently, there have been over 1500 different AMPs 
described (Guaní-Guerra et al., 2010). Because of their great diversity, AMPs classification in 
higher eukaryotes has been hampered; however, five groups have been established based on 
their amino acid sequence and structural conformation; whereas in plants 10 families have 
been classified. Here are some general aspects of AMPs produced by animals and plants, 
emphasizing their action mechanism and their therapeutic and biomedical properties. 
4.1 Animal AMPs 
In animals, AMPs are produced at sites that are in constant contact with microorganisms, 
such as mucosal epithelial cells (respiratory, oral, genitourinary, gastrointestinal, etc.) or 
skin cells. In the case of insects, they are also produced in the fat body and hemocytes; and 
in vertebrates are produced and stored in monocytes, neutrophils, and mast cells, which 
constitute some of the non-oxidative effector mechanisms against potential pathogens. 
Animal AMPs can be produced constitutively or in response to infection (Brogden, 2005). 
4.2 Animal AMPs classification 
AMPs diversity is so large that their classification has been held back; however, five main 
groups are proposed which consist of those found in plants, vertebrates and invertebrates. 
These are described in Table 4, and the main representatives of the groups mentioned. 
Briefly, a group comprises anionic peptides including small peptides rich in glutamic and 
aspartic acid; a second group contains short cationic peptides (<40 residues) which lack 
cysteines and that in some environments adopt certain  α-helical structures; a third group 
includes cationic peptides rich in various amino acids. There is a fourth group of anionic 
and cationic AMPs that present several cysteine residues, and therefore form disulfide 
bonds and stable α-sheets. These include most of the AMPs produced by plants as described 
below. Finally, there is a fifth group containing anionic and cationic peptides, which are 
fragments of larger proteins.  
4.3 Plant AMPs 
Plant AMPs are part of the defense mechanisms of these, they may be expressed 
constitutively or can be induced in response to a pathogen attack, and although lack of the 
sophistication of vertebrate adaptive immunity, they offer "fast" protection against 
pathogens. Compared with the production and action of secondary metabolites, AMPs can  
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Group                             Representative AMPs    Source 
Anionic peptides 
 
Dermacidin 
Maximin H5 
Human sweat glands 
Amphibians 
 
Linear cationic 
peptides with ǂ-
helical structures 
Melittin 
Magainin 2 
Cecropin 37 
Dermaseptin 
Cathelicidin LL37 
Bee venom 
Amphibian skin 
Insects 
Amphibian skin 
Humans 
 
Cationic peptides 
rich in certain amino 
acid residues 
 
Histatin-5 (histidin rich) 
PR-39 (proline and arginine 
rich) 
Indolicin (triptophan rich) 
Human saliva 
Pig neutrophils 
Cattle 
 
Anionic and cationic 
peptides that contain 
cysteine and form 
disulfide bonds 
Brevinin (1 S-S bond) 
Protegrin (2 S-S bonds) 
ǂ and ǃ defensins (3 S-S bonds) 
Defensins and Thionins (>3 S-S 
bonds) 
Drosomycin (>3 S-S bonds) 
Amphibians 
Pigs 
Mammals (ǂ and β), avians 
(ǂ) 
Plants 
Drosophila melanogaster 
Cationic and anionic 
peptides that are 
fragments of larger 
proteins 
 
Lactoferricin from lactoferrin 
 
 
Bovine milk 
Table 4. Animal and plants AMPs classification based on amino acid composition, net 
charge and secondary structure (Epand & Vogel, 1999; Bradshaw, 2003; Brogden, 2005) 
be released immediately after the infection is produced; they are expressed by a single gene 
and therefore require less biomass and energy expenditure (Thomma et al., 2002; Lay & 
Anderson, 2005). Most of characterized plant AMPs to date have a molecular weight in the 
range of 2 to 10 kDa; are basic and contain 4, 6, 8 or 12 cysteines that form disulfide bonds, 
giving them structural and thermodynamic stability (García-Olmedo et al., 2001; Lay & 
Anderson, 2005) 
4.4 Plant AMPs classification 
Plant AMPs are classified based on the identity of their amino acid sequence and the 
number and position of cysteines forming disulfide bonds. So far, 10 families have been 
described in plants, these are listed in Table 5 (García-Olmedo et al., 2001; Lay & Anderson, 
2005). These include lipid transfer peptides (LTPs), thionins, defensins, hevein and knottin 
like proteins, as well as antimicrobial proteins isolated from Macadamia integrifolia (MBP-1) 
and Impatiens balsamina (Ib-AMP). All these AMPs exert their effect at the plasma membrane 
of the microorganisms that they attack, although their action mechanisms vary depending 
on the family. The cyclotides are members of a recently discovered peptide family rich in 
cysteine, commonly found in the Rubiaceae, Violaceae and Cucurbitaceae families; they present 
antibacterial and antiviral activities, as well as insecticide properties; besides containing a 
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head-tail cyclic backbone and a knotted arrangement of three conserved disulfide bonds 
(Daly et al., 2009). 
 
Family 
Amino acid 
number 
Disulfide bonds Acitivity vs. 
LTPs 90–95 3–4 Bacteria and fungi 
Snakins 61–70 6 Bacteria and fungi 
Defensins 45–54 4 Bacteria and fungi 
Thionins 45–47 3–4 Bacteria and fungi 
Hevein-like 43 4 
Gram (+) bacteria and 
fungi 
Knottin-like 36–37 3 
Gram (+) bacteria and 
fungi 
Shepherins** 28–38 0 (linear) Bacteria and fungi 
MBP-1* 33 2 Bacteria and fungi 
Cyclotides 29–31 3 
Bacteria, viruses and 
insects 
Ib-AMP* 20 2 
Gram (+) bacteria and 
fungi 
Table 5. Plant AMPs families (Lay & Anderson, 2005; García-Olmedo et al., 1998; Daly et al., 
2009). * One member family; **two member family, which are derived from a polypeptide 
precursor 
Thionins were the first AMPs whose antimicrobial activity against plant pathogens was 
demonstrated in vitro (García-Olmedo et al., 2001). This class of molecules has been found in 
various plant tissues, such as the seed endosperm, the stem and roots; they present a three-
dimensional structure that can be represented by gamma letter (Ǆ), where the vertical 
portion consists of a pair of antiparallel α-helices and the short horizontal arm consists of an 
antiparallel β-sheet (Thevissen et al., 1996). Thionins belong to a small group of basic 
peptides rich in cysteine that are toxic to bacteria and phytopathogenic fungi (Vignutelli et 
al., 1998; Zasloff, 2002). It has been suggested that toxicity requires the electrostatic 
interaction of the thionins with the negative charges of the membrane, causing the formation 
of pores (Thevissen et al., 1996). 
Plant defensins are AMPs with an approximate molecular weight of 5 kDa, they are 
composed of 45 to 54 amino acids; they are basic and typically have eight cysteines. Ǆ-
purotionina (Ǆ-1P) and Ǆ-hordotionina (Ǆ-1H) were the first isolated defensins, which were 
obtained from wheat and barley grains, respectively. These AMPs have been found in all 
studied plants, even it is hypothesized that they are ubiquitous in the plant kingdom. They 
have been isolated from sorghum, pea, tobacco, potato, petunia, beet, radish and several 
members of the Brassicaceae family (García-Olmedo et al., 1998), also from broad beans (Vicia 
faba) (Zhang & Lewis, 1997) and maize (Zea mays) (Kushmerick et al., 1998). AMPs have been 
detected in various tissues, mainly in those that are most exposed to contact with pathogens 
such as leaf primordia, the cells adjacent to the substomatal cavity, epidermis and stomata; 
in addition to seeds, leaves, pods, tubers, fruit, roots and bark (García-Olmedo et al., 1998; 
Lay & Anderson, 2005). 
In relation to shepherins, they have been isolated from Capsella bursa-pastoris, they are rich in 
glycine and histidine and show activity against Gram negative bacteria and fungi (Park et 
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al., 2000). The snakins are peptides containing 12 cysteines, 6 disulfide bonds and have been 
isolated from potato. They present activity against plant pathogenic fungi and bacteria 
(Berrocal-Lobo et al., 2002). 
4.5 Animal and plant AMPs genes 
With regard to the genes that codify for animals and plants AMPs, they can be found in one 
or more copies with a variable intron number. In animals, it has been found that many of the 
genes that codify for AMPs have κB regulatory sequences, and therefore many of them are 
activated by NF-κB transcription factors, although it has also been reported that in higher 
eukaryotes there are other expression regulatory factors, such as the hypoxia-inducible 
factor (HIF), which regulates the expression of cathelicidins in mammals (Zarember & 
Malech, 2005; Hölzl et al., 2008), and the activator protein 1 (AP-1) transcription factor that 
regulates the expression of mammalian defensins (Wehkamp, 2004). 
4.6 Animal and plant AMPs posttranslational modifications 
Most studied AMPs are the product of larger proteins that contain a signal peptide, a pre-
domain and a region corresponding to the mature peptide. The presence, length and relative 
position of these three regions varies among the different AMPs families, and only the mature 
peptide is the one that interacts with microorganisms (Lay & Anderson, 2005). They can also 
show modifications such as glycosylation, circularization, amidation of the ends and amino 
acid modification including D-amino acids (Boman, 1995; Nissen-Meyer & Nes, 1997). 
4.7 Animal and plant AMPs action mechanisms 
The nature of AMPs, based on their amino acid composition, charge and size allows them to 
be easily inserted into the lipid bilayer membranes of microorganisms. The general 
mechanism by which AMPs damage plasma membranes is considered universal for all 
described peptides, and is based on electrostatic interactions. In the case of bacteria, the 
interaction of cationic AMPs with anionic membrane phospholipids (phosphatidylglycerol 
and cardiolipin), and with the phosphate groups of Gram negative lipopolysaccharide 
(LPS), as well as the interaction with teichoic acids in Gram positive bacteria, occurs through 
electrostatic mechanisms, constituting the first step of action. Subsequently, peptides that 
are in close contact with the bacterial cell must pass through the capsular polysaccharide or 
teichoic and lipoteichoic acids to interact with the plasma membrane. Once the peptides 
have contacted it they can interact with the lipid bilayer. The second step is the 
permeabilizaton of the membrane; this mechanism is given by the formation of pores in the 
membrane due to interactions and arrangements of the AMPs. This leads to cell lysis by 
osmotic shock (Ogata et al., 1992; Boman, 1995, 2003). 
These mechanisms may vary depending on different AMPs types, their concentration and 
the organism with which they interact. Besides, recently novel action mechanisms have been 
described that include the synthesis inhibition of nucleic acids, proteins, the cell wall, as well 
as the activity inhibition of some other enzymes (Bradshaw, 2003; Murray & Liu, 2008). The 
mechanisms related to cell membrane disruption and to intracellular target interactions are 
described below. 
The AMPs interaction with membranes has been studied mainly in cationic peptides with α-
helical structures. Although the interaction mechanism may be different for each type of 
peptide, their main action involves the instability of the outer membrane, translocating it 
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through the outer bilayer (Bradshaw, 2003; Téllez & Castaño, 2010); these mechanisms are 
explained in the "barrel-stave", "toroidal pore", "carpet", "molecular electroporation” and 
perforation of the" lipid raft” models, which are described below. 
4.7.1 “Barrel-stave” model 
This model proposes that initially, a group of cationic AMPs molecules with α-helical 
structures interact with each other on the surface of the plasma membrane to form a 
complex. Subsequently, the peptides are oriented perpendicular to the plane of the 
membrane allowing the hydrophobic region of the peptide to interact with the hydrophobic 
region of the bilayer, while the hydrophilic surface of the peptide is oriented inwards, 
forming a hydrophilic channel that expands along the membrane. In this way, the formed 
protein complex behaves as a pore inserted into the membrane. The formation of these 
channels causes alterations in the membrane potential, provokes the output of solutes and 
eventually results in cell lysis (Zhao et al., 2003) (Figure 3). 
4.7.2 “Carpet” model 
In this model it is proposed that cationic AMPs bind to the phospholipids in the outer layer 
of the membrane covering the bilayer as a "carpet", but without inserting themselves in it. At 
the beginning of the interaction, the peptides orient themselves parallel to the membrane. 
When the peptide reaches a certain critical concentration, the monomers rotate and reorient 
towards the hydrophobic core of the membrane causing the formation of micelles and the 
collapse of the membrane (Shai, 1995). The early stages of the AMP interface with the 
membrane are based on electrostatic interactions between the peptide positive charges and 
the negative charges of the membrane phospholipid heads (Shai, 1995, 1999); while pore 
formation is mainly governed by interactions between the hydrophobic region of the AMP 
and the hydrophobic center of the bilayer (Papo & Shai, 2003). The peptides that are 
characterized by having a "carpet"-type action mechanism have a low affinity for 
zwitterionic lipids in comparison with acidic lipids (Zhao et al., 2003). This model describes 
the action mechanism of most cationic AMPs, including dermaseptin from the skin of 
amphibians and insect cecropin. The "carpet" model (Figure 4) may explains the action 
mechanism of peptides with a size of less than 23 or 24 amino acid residues that do not cross 
the plasma membrane and whose action mechanism cannot be explained by the “barrel-
stave” model (Zhao et al., 2003). 
4.7.3 “Toroidal pore” model 
The "toroidal pore" model explains the action mechanism of cationic peptides with α-helical 
structures and from those that form disulfide bonds. Initially, the peptide orients itself 
parallel to the plane of the plasma membrane and binds to the region of the phospholipid 
polar heads in a functionally inactive state. When the threshold of a peptide-lipid molar 
ratio is exceeded (e.g., 1:30 for magainin 2), the peptides are reoriented perpendicular to the 
plane of the bilayer, and in conjunction with several surrounding lipids they invert 
themselves towards the interior of the membrane’s hydrophobic region. This forms a 
"dynamic supramolecular peptide-lipid complex”, which causes the irreversible rupture of 
the membrane. The transition between the inactive and active state of the peptide bound to 
the membrane depends on AMPs concentration and the phospholipid composition of the 
bilayer (Huang, 2000). 
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Fig. 3. Schematic representation of the "barrel stave" model explaining the interaction of 
antimicrobial peptides with bacterial membranes. In a first step (recruitment), the peptide 
monomers are joined together on the surface of the outer membrane of the bilayer. This 
process is governed primarily by the interaction of the peptide hydrophilic regions (shown 
in black), the recruited peptides are oriented parallel to the plane of the bilayer (panel A), 
when sufficient peptides are recruited (at least three of them) the peptide complex 
undergoes a perpendicular re-orientation to the plasma membrane (panel B), and finally the 
complex enters through the hydrophobic region of the bilayer (inset), forming a channel 
(panel C). Modified from Zhao et al., 2003 
According to this model, the pores are formed by rows of lipids interposed to the peptides, 
which are oriented perpendicularly to the surface of the membrane, allowing the interaction 
of the hydrophilic regions of the pore with the polar heads of the phospholipids; which 
causes the lipid heads and the polar face of the ǂ-helix, in the case of cationic peptides, to 
become oriented towards the pore’s interior. As a result, the outside and interior faces of the 
bilayer become a continuous layer that delimits the interior of the pore. The newly formed 
pore allows for a coupled lipid and peptide transport across the bilayer with an increase of 
transmembrane movement of phospholipids ("flip-flop") and the orientation of the peptide 
monomers towards the interior of the bilayer. This arrangement differs from the classical 
channel depicted in the “barrel-stave” model (Figure 5); where interactions occur mainly 
between the hydrophobic face of the pore and the acyl chains of the bilayer’s lipid core 
(Zhao et al., 2003). The magnitude, duration and required concentration for pore formation 
depends on the peptide, but is generally considered that the multipore state is the most 
stable structure and is formed when high concentrations of the peptide exist. However, 
individual pores may have a short lifetime and allow ion diffusion (Matsuzaki et al., 1997). 
4.7.4 “Molecular electroporation” model 
In this model, cationic AMPs are associated to the bacterial membrane generating an electric 
potential difference across it. The pore is generated when the potential difference reaches 0.2 
V (Murray et al., 2008). 
4.7.5 “Lipid raft” perforation model 
This model proposes that the binding of an amphipathic AMP causes a mass imbalance and 
therefore an increase in the curvature of the membrane, which provides sufficient force to it 
to translocate through itself. Since AMPs self-associate, in this model they would sink into 
the membrane, generating a transient pore in which the peptides would be in both sides of it 
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(Murray & Liu, 2008). Moreover, there is growing evidence that indicates that AMPs have 
intracellular targets in addition to their plasma membrane interactions, because targets have 
been identified within microbial cells, and also because this mechanism explains why AMPs 
can enter the microbial cell without affecting its outer structure by passive transport 
(Nicolas, 2009). 
 
 
Fig. 4. Schematic representation of the “carpet” model explaining the interaction between 
antimicrobial peptides and bacterial membranes. This model describes the interaction that 
occurs between the positive charges of the -helical cationic peptides and negatively 
charged polar phospholipid heads, which are oriented towards the outside of the 
membranes. Bound peptides remain parallel to the outer membrane of the bilayer (panel A), 
when they reach a critical concentration, the peptides rotate on their axis, causing the 
phospholipids bound to them to redirect (panel B), this shift produces the collapse of the 
structure of the plasma membrane and the formation of micelles with a hydrophobic core, 
forming a pore in the membrane (panel C). Modified from Zhao et al., 2003 
 
 
Fig. 5. Schematic representation of the "toroidal pore" model describing the interaction of 
antimicrobial peptides with bacterial membranes. This model, also known as a "two stage" 
model, describes the transition of the peptide from an inactive state to an active state. At low 
concentrations (inactive state), the peptides are oriented parallel to the plane of the bilayer 
(panel A). When they reaches a critical concentration, the peptide molecules are reoriented 
perpendicularly penetrating the hydrophobic region of the bilayer (active state) and 
together with some lipid molecules they adopt a multipore transitional state, known as a 
supramolecular peptide-lipid dynamic complex (panel B '), this produces the irreversible 
rupture of the plasma membrane and an increase in the "transmembranal movement" of 
lipids (two-headed arrow) (panel B). As a result of this increased "transmembranal 
movement" of lipids an orientation of the peptide molecules towards the inner layer of the 
bilayer may occur (panel C). Modified from Zhao et al., 2003 
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Two general mechanisms have been proposed to describe the process by which AMPs enter 
microbial cells: 1) spontaneous assisted translocation by lipids, and 2) a stereospecific 
receptor-mediated endocytosis. These internalization mechanisms vary depending on the 
peptide type and the target cell. In addition, the AMPs amino acid composition plays a 
crucial role in the internalization, since they are composed mainly of basic amino acids 
(principally arginine), AMPs can interact in a better way with membrane lipids allowing 
them to pass inside (Nicolas, 2009). 
Once AMPs access the interior of the microbial cells, they interfere in metabolic functions 
such as: cytoplasm alteration, intracellular content agglutination, signaling pathways 
modification, regulation of transcription and inhibition of the transcription process, cell wall 
synthesis, nucleic acid synthesis, protein synthesis or enzyme activity (Brogden, 2005). 
4.7.6 Other plant and animal AMPs action mechanisms 
It has been reported that some AMPs from plants and insects carry out their effects through 
specific receptors localized in the membranes of some fungi. Such is the case of plant 
defensins RsAFP2 and DmAMP1 from Raphanus sativus and Dahlia merckii respectively, and 
the insect defensin heliomicin from Heliothis virescens; which interact with specific 
sphingolipids of plant and animal pathogenic fungi (Thevissen et al., 2007). 
Many antimicrobial peptides are ineffective in normal mammalian cells. This seems to be 
related mainly to the lipid composition of target membrane (i.e. fluidity, negative charge 
density and the presence or absence of cholesterol), and to present a highly negative 
transmembrane electric potential (Nicolas, 2009). In tumor cells, AMPs interact with the 
membrane of cancer cells, which contain a small amount of phosphatidylserine giving them 
a greater negative charge compared to normal cells. In addition, cancer cells contain O-
glycosylated mucins that attract serines and threonines from the AMPs. Another possible 
explanation for the peptide interaction with cancer cells is the high number of microvilli 
present in them, compared to normal cells, which increases the bonding surface of cancer 
cell membranes for AMPs (Papo & Shai, 2005). 
The action mechanism of AMPs may also vary depending on their concentration, for 
example, at high concentrations the peptides can “carpet” the plasma membrane quickly 
generating micelles, causing cell lysis. On the other hand, at low concentrations, AMPs can 
slowly form pores in the membrane, they can also insert their polar region between 
phospholipids through the membrane from side to side causing the thinning of it, or they 
can cross the cell membrane without causing damage and attack or block an intracellular 
target (Hancock & Rozek, 2002; Brogden, 2005). It has also been shown that some AMPs 
regulate diverse functions of innate immunity such as neutrophil, mast cell or monocyte 
chemotaxis; they induce phagocytosis, are involved in tissue repair and angiogenesis, they 
can show anti-inflammatory properties and in some cases stimulate the production of 
cytokines and increase vascular permeability (Nicolas, 2009; Téllez & Castaño, 2010; Hölzl, 
2008). 
4.8 Resistance mechanisms towards animal and plant AMPs 
Although AMPs production is an essential component of the plant and animal immunity, 
microorganisms, particularly bacteria, have developed various resistance mechanisms to 
them. These include mechanisms against AMP adhesion and insertion, as well as 
mechanisms that modify membrane permeability. In this sense, some bacteria have 
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developed modifications in the net charge on their surface, changes in membrane proteins, 
proteolytic enzyme production, removal of AMPs by transporters, etc. (Brogden, 2005). 
4.9 Potential application of plant and animal AMPs in biomedical therapies 
The potential usefulness of plant and animal AMPs clinical purposes resides in their use as 
antimicrobial agents, alone or in synergy with existing antibiotics. Similarly they can be 
employed as immunomodulatory agents or bacterial toxin neutralizers. Because many of 
them have low toxicity towards normal eukaryotic cells, but not for tumor cells, their use as 
anticancer drugs has been considered (Schweizer, 2009). 
AMPs offer a good alternative for treating infections in relation to conventional antibiotics 
based on their broad spectrum activity and quick efficiency. However, very few plant and 
animal AMPs or synthetic derivatives of these have applications in clinical trials (Gordon et 
al., 2005). This follows the fact that they are susceptible to proteolysis, and that because of 
their chemical characteristics, their activity depends on the serum concentration of salts, or 
the pH of the medium in which they occur. For this reason the most promising AMPs in 
clinical evaluations are the ones that apply topically (Hancock & Sahl, 2006). 
However, despite promising AMPs application, there are none currently approved for 
human use by the Food and Drug Administration (FDA). Only an AMP with topical 
application has shown efficiency in Phase III trials: AMP MX-226 (Omiganan 
pentahydrochloride, 1% gel; Migenix Laboratories), a synthetic peptide based on bovine 
indolicin and developed to prevent infections caused by the use of catheters. AMP synthetic 
derivatives are based on modifications to their three-dimensional structure and their 
biochemical properties, in order to show more stability and activity in different 
environments (Hancock & Sahl, 2006; Marr et al., 2006; Téllez & Castaño, 2010). 
Additionally, currently the possibility of inducing the endogenous production of AMPs is 
being considered, such is the case for the administration of sodium butyrate to induce the 
production of intestinal AMPs for the treatment of infectious or inflammatory diseases 
(Guaní-Guerra et al., 2010). 
In the case of plant biotechnology transgenic plants resistant to diseases and pests have been 
produced through the introduction of AMPs genes from other plant species or even human 
defensins have been expressed in experimental models, and a better response to the attack 
of fungal pathogens has been observed (Aerts et al., 2007). Moreover, through 
biotechnological approaches, plant defensins and thionins have been expressed in 
mammalian cells in our working group; which showed activity against bacteria, fungi and 
tumor cells (Anaya-López et al., 2006; Loeza-Ángeles et al., 2008). 
Among the studies that have been done with transgenic animals, those that demonstrate the 
protection conferred by human lactoferrin expressed in bovine mammary gland, conveying 
a delayed onset of clinical signs and inflammation caused by intramammary bacteria, stand 
out (Simojoki et al., 2010). In addition, bovine lactoferricin has been used in aquaculture to 
produce fish resistant to various infections (Lin et al., 2010). 
5. Conclusion 
AMPs are structurally diverse molecules, whose characteristics place them as a current and 
potential alternative to combat infections caused by pathogens resistant to conventional 
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antibiotics. In addition, diverse AMPs have shown biological properties different to 
antimicrobial activity, which positions them as tools for new biomedical therapies such as 
the modulation of the immune response, improved conventional antibiotic treatments, 
development of anticancer and anti-inflammatory therapies, the regulation of blood 
pressure and other biotechnological developments. Therefore, AMPs benefits in the 
biomedical area are well known; however, for the therapeutic application to succeed there is 
a multitude of their effects remains to be studied, as well as their biological and chemical 
characteristics in order to elucidate their action mechanisms. 
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